ANDA REPOSITORY
GenericsANDA REPOSITORY is a generic drug manufacturer focused on Infectious Disease, Dermatology, Respiratory.
Upcoming FDA Decisions
Full Calendar →ANDA REPOSITORY's Key Drugs
ANDA REPOSITORY's core commercial portfolio centers on FLAC, DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
ANDA REPOSITORY's Recent FDA Approvals
New NDA/BLA approvals for ANDA REPOSITORY over the last two years — novel drugs only, excluding generics and label supplements.
ANDA REPOSITORY's Therapeutic Areas
ANDA REPOSITORY's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ANDA REPOSITORY's Top Competitors
ANDA REPOSITORY's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ANDA REPOSITORY Pipeline Snapshot
Active clinical trials for ANDA REPOSITORY across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FLAC leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 1994-01-27
- Latest
- 2025-12-22
- Applications
- 22